Yuliya Berd

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

Joachim Sieper, Désirée van der Heijde, Maxime Dougados et al. · Arthritis & Rheumatology · 2015 · 224 citations · Full text

Medicine, Pharmacotherapy, Musculoskeletal Medicine +13

The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial

Anders Bonde Jensen, Christopher Wynne, Guillermo Ramírez et al. · Clinical Breast Cancer · 2010 · 145 citations

Medicine, Oncology, Pharmacotherapy +14

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study

Abraham Adunsky, Julie Chandler, Norman Heyden et al. · Archives of Gerontology and Geriatrics · 2010 · 65 citations

Veterinary Medicine, Orthopedic Surgery, Pharmacotherapy +5

Evaluation of the safety, pharmacokinetics and treatment effects of an α_νβ₃ integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases

Mark Rosenthal, Peter J. Davidson, Frédéric Rolland et al. · Asia-Pacific Journal of Clinical Oncology · 2010 · 51 citations

Medicine, Pharmacokinetics, Pharmacology +13

Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial

A. B. Jensen, N. Olmeo, Christopher Wynne et al. · Journal of Clinical Oncology · 2008 · 21 citations

Medicine, Oncology, Pharmacology +17